Quarterly report pursuant to Section 13 or 15(d)

RESTATEMENT (Schedule of Impact of Restatement in Company's Condensed Unaudited Consolidated Financial Statements) (Details)

v3.20.4
RESTATEMENT (Schedule of Impact of Restatement in Company's Condensed Unaudited Consolidated Financial Statements) (Details) - USD ($)
3 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Sep. 30, 2020
Sep. 30, 2019
Statement of Operations        
Amortization and depreciation $ 451 $ 10,878    
Total Operating Expense 284,465 282,002    
Income/(Loss) from continuing operations before income taxes 35,424 24,598    
Net Income/(Loss) 35,424 1,172    
Net Income/(Loss) attributable to common stockholders $ 25,078 $ (9,172)    
Income/(Loss) from continuing operations $ 0.00 $ 0.00    
Income/(Loss) per common share - basic and diluted $ (0.00) $ 0.00    
Statement of Changes in Stockholders' Equity        
Additional Paid in Capital $ 15,266,718   $ 15,266,718  
Accumulated Deficit (16,020,417)   (16,055,841)  
Total Stockholders' Deficit (751,372) $ (1,176,209) (786,796) $ (1,177,381)
Total Liabilities and Stockholders' Deficit 332,749   $ 393,332  
Statement of Cash Flow        
Net Income/(Loss) $ 35,424 1,172    
As previously reported [Member]        
Statement of Operations        
Amortization and depreciation   49,234    
Total Operating Expense   320,358    
Income/(Loss) from continuing operations before income taxes   (13,758)    
Net Income/(Loss)   (37,184)    
Net Income/(Loss) attributable to common stockholders   $ (47,528)    
Income/(Loss) from continuing operations   $ 0.00    
Income/(Loss) per common share - basic and diluted   $ 0.00    
Statement of Changes in Stockholders' Equity        
Additional Paid in Capital   $ 15,641,402    
Accumulated Deficit   (16,258,294)    
Total Stockholders' Deficit   (614,565)    
Total Liabilities and Stockholders' Deficit   893,899    
Statement of Cash Flow        
Net Income/(Loss)   (37,184)    
Amortization of ReadyMed software platform   38,356    
Supplemental disclosures of non-cash investing and financing activities:        
Common stock issued for ReadyMed platform   600,000    
Adjustment [Member]        
Statement of Operations        
Amortization and depreciation   (38,356)    
Total Operating Expense   (38,356)    
Income/(Loss) from continuing operations before income taxes   38,356    
Net Income/(Loss)   38,356    
Net Income/(Loss) attributable to common stockholders   $ 38,356    
Income/(Loss) from continuing operations   $ 0.00    
Income/(Loss) per common share - basic and diluted   $ 0.00    
Statement of Changes in Stockholders' Equity        
Additional Paid in Capital   $ (600,000)    
Accumulated Deficit   38,356    
Total Stockholders' Deficit   (561,644)    
Total Liabilities and Stockholders' Deficit   (561,644)    
Statement of Cash Flow        
Net Income/(Loss)   38,356    
Amortization of ReadyMed software platform   (38,356)    
Supplemental disclosures of non-cash investing and financing activities:        
Common stock issued for ReadyMed platform   (600,000)    
As Restated [Member]        
Statement of Operations        
Amortization and depreciation   10,878    
Total Operating Expense   282,002    
Income/(Loss) from continuing operations before income taxes   24,598    
Net Income/(Loss)   1,172    
Net Income/(Loss) attributable to common stockholders   $ (9,172)    
Income/(Loss) from continuing operations   $ 0.00    
Income/(Loss) per common share - basic and diluted   $ 0.00    
Statement of Changes in Stockholders' Equity        
Additional Paid in Capital   $ 15,041,402    
Accumulated Deficit   (16,219,938)    
Total Stockholders' Deficit   (1,176,209)    
Total Liabilities and Stockholders' Deficit   332,255    
Statement of Cash Flow        
Net Income/(Loss)   1,172    
Amortization of ReadyMed software platform      
Supplemental disclosures of non-cash investing and financing activities:        
Common stock issued for ReadyMed platform